Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
Holding JNJ?
Track your performance easily
JNJ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$143.13 - $168.85
Previous Close$167.07
Volume4.72M
Average Volume (3M)6.84M
Market Cap
$402.18B
Enterprise Value$418.19B
Total Cash (Recent Filing)$25.48B
Total Debt (Recent Filing)$41.49B
Price to Earnings (P/E)24.1
Beta0.24
Next Earnings
Oct 15, 2024EPS Estimate
$2.18Last Dividend Ex-Date
Aug 27, 2024Dividend Yield2.91%
Share Statistics
EPS (TTM)6.92
Shares Outstanding2,407,243,667
10 Day Avg. Volume5,602,174
30 Day Avg. Volume6,838,913
Standard Deviation0.05
R-Squared0.30
Alpha0.00127
Financial Highlights & Ratios
Price to Book (P/B)5.62
Price to Sales (P/S)4.64
Price to Cash Flow (P/CF)17.70
P/FCF Ratio21.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.83
Enterprise Value/Gross Profit7.14
Enterprise Value/Ebitda20.60
Forecast
1Y Price Target
$171.83Price Target Upside3.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Johnson & Johnson News
Bulls Say, Bears Say
Bulls Say
Legal ResolutionJNJ has cleared the voting hurdle to advance the proposed $6.5bn plan to resolve ovarian cancer talc claims, with more than 75% of the plaintiffs voting in favor.
Market PenetrationJNJ's newer MM portfolio, including Darzalex and Carvykti, has achieved 46% penetration in total MM and 3L+ MM treatment, with Darzalex being #2 in overall MM market penetration.
Medtech GrowthManagement is confident in Medtech growth acceleration and is bullish on the 2025 outlook with key growth drivers including Varipulse US approval.
Bears Say
EarningsAdjusted operational EPS guidance has also been revised and now stands at $10.00-$10.10, down from $10.60-$10.75 previously.
Legal ChallengesThe settlement plan likely still faces significant legal challenges from plaintiffs opposing the terms.
Sales GrowthJNJ expects Innovative Medicine sales growth to be lower in 2H'24 compared to 1H'24 due to the anticipated biosimilar entry of Stelara in Europe.
---
Ownership Overview
0.20% Insiders
18.92% Mutual Funds
35.10% Other Institutional Investors
45.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $143.13 and its highest was $168.85 in the past 12 months.
What is Johnson & Johnson’s market cap?
Currently, no data Available
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Oct 15, 2024 which is in 26 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Jul 17, 2024. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.711 by $0.109.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.24 which represents an annual dividend yield of 2.91%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is $2.18.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,407,243,700 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.82 in its last earnings report, beating expectations of $2.711. Following the earnings report the stock price went up 3.69%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Among the largest hedge funds holding Johnson & Johnson’s share is Fisher Asset Management LLC. It holds Johnson & Johnson’s shares valued at 1B.
---
Johnson & Johnson Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$171.83 (3.42% Upside)
$171.83 (3.42% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 91%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 500.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $930.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.75%
12-Months-Change
Fundamentals
Return on Equity
22.34%
Trailing 12-Months
Asset Growth
-5.53%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
---
JNJ Company Deck
---
JNJ Earnings Call
Q2 2024
0:00 / 0:00
---
JNJ Sales Breakdown
64.30% Innovative Medicine
35.70% MedTech
---
JNJ Stock 12 Month Forecast
Average Price Target
$171.83
▲(3.42% Upside)
Technical Analysis
Best Analysts Covering JNJ
1 Year
1 Year Success Rate
23/23 ratings generated profit
1 Year Average Return
+10.08%
reiterated a buy rating 4 months ago
Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +10.08% per trade.
---